Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117 Jun 17, 2021
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Jun 8, 2021
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jun 4, 2021
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis May 20, 2021
Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia May 18, 2021
Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia May 12, 2021
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update May 7, 2021
